Predict your next investment

Venture Capital
ihcv.co.il

See what CB Insights has to offer

Investments

27

Portfolio Exits

5

Funds

2

About Israel Healthcare Ventures

Israel Healthcare Ventures, founded in 2001, is a venture capital firm that aims to focus on all stages of a company from seed to corporate acquisition. The firm's areas of focus from an investment perspective include medical devices, biotechnology, pharmaceuticals, life sciences, nanotechnology, and medical-related IT companies. Geographically, Israel Healthcare Ventures invests in companies based in Israel, and the firm prefers to hold a board seat in its portfolio companies.

Israel Healthcare Ventures Headquarter Location

32 Harbarzel St.

Tel Aviv, 69710,

Israel

+972 3 648-8566

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Israel Healthcare Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Israel Healthcare Ventures in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Israel Healthcare Ventures News

NiTi Surgical Solutions Secures $18.5 Million in Series F Financing

May 31, 2019

Company Leading Innovation in Colorectal Surgery August 12, 2009 07:00 AM Eastern Daylight Time CHESTERFIELD, Mo. & NETANIA, Israel--( BUSINESS WIRE )--NiTi™ Surgical Solutions, an innovative surgical device company, today announced the completion of a financing round, in which the company raised approximately $18.5 million. The round was led by Forbion Capital Partners, based in Naarden, The Netherlands, with additional participation from existing investors including: Evergreen Venture Partners, Israel Healthcare Ventures (IHCV), MBVC and Alice Lab, and SCP Vitalife. In conjunction with this closing, Avi Molcho, MD, venture partner at Forbion, will join NiTi’s Board of Directors. Proceeds from this financing will be used to support the marketing and roll-out of the company’s ColonRing™ and to advance ongoing and new research and development of BioDynamix™ Anastomosis Technology programs. The ColonRing was recently launched in the US, and the device has been very well received by users due to its excellent wound healing capabilities. The ColonRing represents a revolutionary closure technology for surgeries such as colon cancer surgery and has been successfully applied in over 2,200 patients. “This successful financing is a direct result of NiTi Surgical Solutions’ well-executed business strategy and growing market presence in anastomosis, with its proprietary BioDynamix Technology,” stated Hadar Ron, MD, managing director of IHCV and chairman of the Board of Directors for NiTi. “By successfully developing and commercializing much-needed, state-of-the-art medical devices to optimize surgical outcomes for patients, NiTi is emerging as a significant player in the surgical closure technology market.” NiTi Surgical Solutions' shape memory surgical rings, clips, and appliers represent the next generation in internal tissue-closure devices. These advanced devices are designed for treatment of colorectal, gastric and upper gastrointestinal disease requiring surgical anastomosis. The company`s unique line of products utilizes nitinol-based elements to press together the ends of resected tissue, enabling natural reconnection and healing of the intestine after removing a section as part of a surgery, such as in colon cancer treatment. “NiTi offers a compelling investment thesis for us with its unique BioDynamix Anastomosis Technology platform and strong clinical support from leading surgeons across the globe,” stated Dr. Molcho. “We truly believe that NiTi’s technology, starting with the recently launched ColonRing, offers surgeons a revolutionary approach to anastomosis that will permanently change the current surgical paradigm for the better.” The company’s FDA-cleared, CE-marked ColonRing™ represents the first major advancement in colorectal surgery in more than 30 years and addresses the significant drawbacks of traditional staples. “NiTi’s ability to garner additional financing from leading biotech investors underscores the strength and utility of our proprietary technology, and the promise and potential for our products to meet the critical needs of surgeons, physicians, and patients,” said Itay Itzhaky, chief executive officer of NiTi Surgical Solutions. “Our first marketed product, the novel ColonRing with BioDynamix Anastomosis Technology, is one of several innovative nitinol devices we expect to bring to market. This recent round of financing will help us broaden our sales and marketing presence, as well as further our research and development activities to support a variety of advanced surgical products in the coming months.” About ColonRing™ with BioDynamix™ Anastomosis Technology NiTi Surgical Solutions has leveraged the features of Nitinol in the ColonRing technology. In the ColonRing, the Nitinol leaf springs stretch to open the ring for placement in the bowel, and then gradually return to their original closed position, adapting to variations in tissue thickness and accommodating compressed tissue. The Nitinol leaf springs continuously apply constant force range of pressure around the full circumference of the anastomosis. As the compression progresses over several days, the tissue trapped within the ring becomes necrotic, while healthy tissue is generated along the ring’s outer perimeter. In human trials and clinical practice, BioDynamix Anastomosis technology has shown the potential to provide durable anastomosis with encouraging results in the rate of complications, particularly in low cases. Colonoscopic examination at six months demonstrated an effective, seamless anastomosis with excellent wound healing. In animal trials, ColonRing resulted in a time zero anastomotic burst strength up to three times stronger than circular staplers. In addition, histologic examination of resected anastomoses showed complete reepithelialization of the mucosa and a uniform anastomosis showing full recovery to the natural multi-layer tissue structure. About Forbion Capital Partners Forbion is a leading Life Sciences Fund that invests in drug development companies and medical device companies in Europe and in the US/Canada. The Fund focuses their investment strategy on high medical needs where a substantial improvement over current treatments can be realized. Forbion has currently over EUR 300m under management and has built a strong financial track record since the late nineties. Forbion is an active, hands-on investor that supports its companies to achieve their corporate objectives by sharing its financial, clinical, regulatory and marketing experience. Forbion is currently investing from its Forbion Capital Fund II, a new fund that has realized a first close in November 2008. For more information please visit www.forbion.com . About NiTi™ Surgical Solutions NiTi Surgical Solutions is focused on the BioDynamix™ of natural healing, offering state-of-the-art medical devices to optimize surgical outcomes for patients and physicians. NiTi Surgical Solutions currently markets its novel ColonRing™ device - the next generation of closure technology for colorectal resection - providing surgeons with a potentially safer and more effective alternative to standard staple-dependent closure techniques. NiTi continues to expand its core competencies and innovative technology to a variety of advanced surgical products, techniques, and procedures. NiTi Surgical Solutions is a privately held, venture backed company with headquarters in Israel and the U.S. For more information, please visit www.nitisurgical.com .

Israel Healthcare Ventures Investments

27 Investments

Israel Healthcare Ventures has made 27 investments. Their latest investment was in Gamida Cell as part of their Unattributed VC on June 6, 2017.

CBI Logo

Israel Healthcare Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/19/2017

Unattributed VC

Gamida Cell

$40M

No

Clal Biotechnology Industries, Israel Biotech Fund, Novartis, Shavit Capital Fund, and VMS Asset Management

2

7/30/2012

Unattributed VC

NanoPass Technologies

Yes

D-Partners Ltd, Elcam Medical, Ofer Hi-Tech, and WFD Ventures

5/15/2012

Series E

Gamida Cell

$10M

No

5/2/2011

Unattributed - II

Subscribe to see more

$99M

Subscribe to see more

10

12/30/2010

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/19/2017

7/30/2012

5/15/2012

5/2/2011

12/30/2010

Round

Unattributed VC

Unattributed VC

Series E

Unattributed - II

Seed

Company

Gamida Cell

NanoPass Technologies

Gamida Cell

Subscribe to see more

Subscribe to see more

Amount

$40M

$10M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Clal Biotechnology Industries, Israel Biotech Fund, Novartis, Shavit Capital Fund, and VMS Asset Management

D-Partners Ltd, Elcam Medical, Ofer Hi-Tech, and WFD Ventures

Sources

2

10

10

Israel Healthcare Ventures Portfolio Exits

5 Portfolio Exits

Israel Healthcare Ventures has 5 portfolio exits. Their latest portfolio exit was InMode on August 08, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/8/2019

IPO

$991

14

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/8/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

14

10

10

10

10

Israel Healthcare Ventures Fund History

2 Fund Histories

Israel Healthcare Ventures has 2 funds, including Israel HealthCare Ventures.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2000

Israel HealthCare Ventures

Early-Stage Venture Capital

$70M

1

Israel HealthCare Ventures II

Subscribe to see more

$99M

10

Closing Date

12/31/2000

Fund

Israel HealthCare Ventures

Israel HealthCare Ventures II

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Amount

$70M

$99M

Sources

1

10

Israel Healthcare Ventures Team

3 Team Members

Israel Healthcare Ventures has 3 team members, including current Managing Partner, Hadar Ron.

Name

Work History

Title

Status

Hadar Ron

Managing Partner

Current

Avner Lushi

Managing Director

Current

Eran Perry

Managing Director

Current

Name

Hadar Ron

Avner Lushi

Eran Perry

Work History

Title

Managing Partner

Managing Director

Managing Director

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.